Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

August 9, 2022 6:50 AM EDT

   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share

   Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY®

   First half 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $5.60 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Companys history

   First half 2022 revenue of $190 million exceeds full year 2021 revenue of $171.5 million

 ... More